Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) has announced the successful completion of its acquisition of Sage Therapeutics, Inc. (Nasdaq: SAGE). This move significantly strengthens the company's portfolio, allowing it to diversify its revenue streams and enhance its strategic growth plan.
According to Jack Khattar, President and CEO of Supernus, the integration of Sage is expected to bolster their psychiatry offerings. By adding ZURZUVAE (zuranolone) capsules, the first FDA-approved oral treatment for postpartum depression, Supernus is positioned to increase both its market presence and financial performance.
Strategic Goals of the Acquisition
The acquisition brings several strategic advantages to Supernus:
- It enhances their psychiatry portfolio substantially, providing access to innovative solutions that were previously unavailable.
- This acquisition diversifies the company's revenue base, including revenue generated through collaboration with Biogen, Inc. for ZURZUVAE.
- The combined product range with existing growth products such as Qelbree, ONAPGO, and GOCOVRI positions Supernus for remarkable future growth.
- Furthermore, existing operational structures are expected to generate cost synergies of up to $200 million annually.
The Offer and Acquisition Details
Under the terms of the acquisition, shareholders of Sage received an offer priced at $8.50 per share, cash payment, along with a contingent value right (CVR) that could yield up to $3.50 depending on specific performance milestones.
This strategic offer was tendered to all outstanding shares of Sage, with a majority of shares validly accepted. The offer's successful completion allows Supernus to merge its wholly-owned subsidiary with Sage, which now operates as a part of Supernus.
Milestones and Future Payments
As part of the contingent value rights arrangement, Sage's shareholders may receive additional payments based on the achievement of various sales milestones related to ZURZUVAE:
- $0.50 for ZURZUVAE's first commercial sale in Japan, expected by mid-2026.
- $1.00 if annual net sales exceed $250 million by the end of 2027.
- Another $1.00 for sales surpassing $300 million by the end of 2028.
- A fourth payment of $1.00 is contingent upon exceeding $375 million in sales by the end of 2030.
These milestones accentuate the growth potential for ZURZUVAE as it aims to deliver impactful results in the market.
Advisory Support
Supernus Pharmaceuticals received strategic advice from Moelis & Company LLC, while Sage was supported by Goldman Sachs & Co. LLC during this significant transaction. Legal services were rendered by Saul Ewing LLP for Supernus and Kirkland & Ellis LLP for Sage.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals specializes in developing and marketing solutions for central nervous system (CNS) disorders. Their product lineup caters to various conditions including ADHD, Parkinson’s disease-related disorders, epilepsy, and migraine, showcasing a commitment to addressing critical health challenges.
The acquisition of Sage Therapeutics only strengthens their resolve to deliver innovative treatments and expand their influence in the CNS market. This progressive step confirms their dedication to improving patient outcomes through advanced therapies.
Frequently Asked Questions
What was the strategic significance of the Sage acquisition?
The acquisition allows Supernus to enhance its psychiatry portfolio and introduce ZURZUVAE, aiming for significant revenue growth.
How will shareholders of Sage benefit from the acquisition?
Sage shareholders will receive $8.50 per share in cash alongside contingent value rights that can yield further payments based on ZURZUVAE sales milestones.
What future milestones should shareholders be aware of?
Shareholders could receive payments for ZURZUVAE sales reaching specific thresholds from Japan's market entry through 2030.
Who provided financial advice during the acquisition process?
Moelis & Company LLC advised Supernus, while Goldman Sachs & Co. LLC advised Sage during this acquisition.
What is the core focus of Supernus Pharmaceuticals?
Supernus is dedicated to developing treatments for CNS disorders, with a portfolio that includes therapies for ADHD, epilepsy, and depression, among others.
